Get started
Tango Therapeutics, Inc.Tango Therapeutics, Inc.Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

TNGX chart


Full chart

TNGX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪303.99 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.17 USD
Net income (FY)
‪−101.74 M‬ USD
Revenue (FY)
‪36.53 M‬ USD
Shares float
‪59.11 M‬
Beta (1Y)
2.25

Employees


Employees (FY)
140
Change (1Y)
+30 +27.27%
Revenue / Employee (1Y)
‪260.91 K‬ USD
Net income / Employee (1Y)
‪−726.74 K‬ USD

About Tango Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Barbara L. Weber
Website
tangotx.com
Headquarters
Boston
Founded
2017
FIGI
BBG00WFDDRS0
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

TNGX news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of TNGX is 2.74 USD — it has decreased by −12.65% in the past 24 hours. Watch Tango Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Tango Therapeutics, Inc. stocks are traded under the ticker TNGX.
TNGX stock has fallen by −49.82% compared to the previous week, the month change is a −60.14% fall, over the last year Tango Therapeutics, Inc. has showed a −69.79% decrease.
We've gathered analysts' opinions on Tango Therapeutics, Inc. future price: according to them, TNGX price has a max estimate of 16.00 USD and a min estimate of 8.00 USD. Watch TNGX chart and read a more detailed Tango Therapeutics, Inc. stock forecast: see what analysts think of Tango Therapeutics, Inc. and suggest that you do with its stocks.
TNGX reached its all-time high on Sep 17, 2021 with the price of 18.84 USD, and its all-time low was 2.47 USD and was reached on May 31, 2023. View more price dynamics on TNGX chart.
See other stocks reaching their highest and lowest prices.
TNGX stock is 10.70% volatile and has beta coefficient of 2.25. Track Tango Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Tango Therapeutics, Inc. there?
Today Tango Therapeutics, Inc. has the market capitalization of ‪303.22 M‬, it has decreased by −9.22% over the last week.
Yes, you can track Tango Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Tango Therapeutics, Inc. is going to release the next earnings report on Mar 31, 2025. Keep track of upcoming events with our Earnings Calendar.
TNGX earnings for the last quarter are −0.27 USD per share, whereas the estimation was −0.37 USD resulting in a 26.37% surprise. The estimated earnings for the next quarter are −0.34 USD per share. See more details about Tango Therapeutics, Inc. earnings.
Tango Therapeutics, Inc. revenue for the last quarter amounts to ‪11.61 M‬ USD, despite the estimated figure of ‪8.07 M‬ USD. In the next quarter, revenue is expected to reach ‪8.21 M‬ USD.
TNGX net income for the last quarter is ‪−29.17 M‬ USD, while the quarter before that showed ‪−25.55 M‬ USD of net income which accounts for −14.15% change. Track more Tango Therapeutics, Inc. financial stats to get the full picture.
No, TNGX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 140.00 employees. See our rating of the largest employees — is Tango Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Tango Therapeutics, Inc. EBITDA is ‪−137.20 M‬ USD, and current EBITDA margin is −305.96%. See more stats in Tango Therapeutics, Inc. financial statements.
Like other stocks, TNGX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Tango Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Tango Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Tango Therapeutics, Inc. stock shows the strong sell signal. See more of Tango Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.